4.4 Article

Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice

Journal

INFECTION GENETICS AND EVOLUTION
Volume 45, Issue -, Pages 447-453

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.meegid.2016.10.006

Keywords

Toxoplasma gondii; Recombinant virus; CAV-2-ROP16; Vaccine; Mice

Funding

  1. National Program for High Technology Research [2011AA10A215]
  2. FOK YING TUNG Education Foundation [141029]
  3. National Scientific and Technological Planning Project of Guangdong Province [2014A020214007]
  4. Natural Science Foundation of Guangdong Province [2016A030313396]
  5. Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences [SKLVEB2015KFKT002]
  6. Special Fund for Agro-scientific Research in the Public Interest [201303042]
  7. Huizhou Science And Technology Projects [2015B040009001]
  8. Project of Guangzhou Zoo [201604]
  9. Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, PR China
  10. National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, PR China
  11. Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, PR China

Ask authors/readers for more resources

We previously demonstrated that the survival time of BALB/c mice challenged with Toxoplasma gondii RH strain was prolonged by immunising the mice with a eukaryotic vector expressing the protein ROP16 of T.gondii. Building upon previous findings, we are exploring improved vaccination strategies to enhance protection. In this work, a novel recombinant canine adenovirus type 2 expressing ROP16 (CAV-2-ROP16) of T. gondii was constructed and identified to express ROP16 in Madin-Darby canine kidney cells (MDCK) cells by western blot (WB) and indirect immunofluorescence (IFA) assays. Intramuscular immunisation of BALB/c mice with CAV-2-ROP16 was performed to evaluate the humoral and cellular immune responses. This vaccination triggered significant humoral and cellular responses, including ROP16-stimulated lymphoproliferation (P < 0.05). Compared to control groups, the CAV-2-ROP16 immunised mice had high production of IFN-gamma, IL-2 and IL-12 (P < 0.05), with a predominance of IgG2a production, but not IL-10 (P > 0.05), revealing that a predominant Th1-type response had developed. The cell-mediated cytotoxic activity with high levels of IFN-gamma and TNF-alpha was significantly increased in both CD4(+) and CD8(+) T-cell compartments in the mice immunised with CAV-2-ROP16 (P < 0.05), compared to three control groups. In addition, when immunised mice were challenged with the RH strain of T.gondii, they showed a significantly increased survival rate (25%) 80 days post infection compared with control mice that all died within seven days (P < 0.05). The 25% protection rate elicited by the recombinant virus CAV-2-ROP16 has not been achieved in the field of anti-T.gondii vaccination until now. Our work presents the successful use of recombinant virus CAV-2-ROP16 in vaccination protocols to protect against intraperitoneal challenge with the virulent RH strain of T.gondii. This system was shown to be extremely efficient in eliciting humoral and cellular immune responses that led to a significant improvement in survival time in mice. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available